Certara Posts Q2 Loss, Reaffirms Guidance, and Authorizes $50M Buyback
CERT sits 47% above its 52-week low of $4.45.
Summary
Certara reported a Q2 net loss of $6.1M on 1% revenue growth, reaffirmed 2026 guidance, and authorized an additional $50M share buyback. The quarter included a $49.2M loss from discontinued operations.
Key Events · Earnings and Guidance · CERT
-
Q2 Revenue Misses, Loss Widens
Revenue grew 1% YoY to $93.3M, but net loss from continuing operations was $6.1M vs. a $1.5M profit a year ago. Including discontinued operations, net loss was $55.3M.
-
Full-Year Guidance Reaffirmed
Management reaffirmed its 2026 revenue guidance despite the weak Q2, implying a significant ramp in the second half of the year.
-
$50M Share Buyback Authorized
The board authorized an additional $50 million share repurchase program on August 3, 2026, adding to the existing program that was exhausted in Q2.
-
Discontinued Operations Loss
The sale of the Regulatory and Medical Writing business resulted in a $49.2M after-tax loss, including a $65.5M pretax loss on disposal.
Analysis · CERT · Technology
Certara's Q2 results underscore persistent headwinds: revenue inched up just 1% to $93.3M, while the company swung to a $6.1M net loss from continuing operations. The bottom line took an additional blow from a $49.2M loss tied to the sale of its medical writing business. Despite the soft quarter, management reaffirmed full-year revenue guidance, signaling confidence in a second-half rebound. The board also authorized an additional $50 million share repurchase program, which could lend support to the stock but also raises questions about capital allocation priorities given the operating losses. The filing further discloses large equity grants to the new CEO, aligning his incentives with shareholders but adding potential dilution.
At the time of this filing, CERT was trading at $6.55 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.45 to $13.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.